FDA Warns Of Hidden Drug Ingredients In Dr Ergin’s SugarMD Glucose Support
The U.S. Food and Drug Administration (FDA) in a press statement on Monday has cautioned consumers against using Dr Ergin’s SugarMD Advanced Glucose Support, a product marketed for managing blood glucose levels. The warning is a result of concerns about undisclosed drug ingredients found in the product.
Dr Ergin’s SugarMD Advanced Glucose Support may have been purchased through various channels, including the website www.sugarmds.com, and potentially in select retail stores. FDA laboratory analysis has uncovered that this product contains glyburide and metformin, both of which are active ingredients found in FDA-approved prescription medications designed for the treatment of type 2 diabetes. Importantly, glyburide and metformin are not available over-the-counter and require a valid prescription from a healthcare provider.
The presence of glyburide in Dr. Ergin’s SugarMD Advanced Glucose Support raises significant health concerns, as it can potentially lead to perilous and life-threatening consequences. One of the primary risks associated with glyburide is a dangerous drop in blood sugar levels, a condition known as hypoglycemia. Symptoms of hypoglycemia include a rapid heartbeat, trembling, sweating, anxiety, irritability, confusion, dizziness, drowsiness, headaches, and an increased sense of hunger. In severe cases, hypoglycemia can lead to seizures, coma, or even prove fatal.
Metformin, the other undisclosed ingredient, also poses a serious risk to consumers. It is known for causing a rare but grave side effect called lactic acidosis, characterized by a dangerous buildup of lactic acid in the bloodstream. If left untreated, lactic acidosis can result in fatalities. Indications of this condition include nausea, vomiting, fatigue, body aches, breathing difficulties, abdominal pain, and rapid, deep breathing. Additionally, when taken in conjunction with other blood sugar-lowering medications, metformin can lead to hypoglycemia, compounding the associated risks.
It is crucial for patients to openly discuss all medications they are taking, even nonprescription drugs, with their healthcare providers. When the presence of glyburide or metformin in a product is not disclosed, patients and their healthcare providers may inadvertently administer a higher combined dose of diabetic medications, potentially leading to hypoglycemia or lactic acidosis. Individuals with chronic kidney disease face the greatest risks associated with both glyburide and metformin, the regulatory body suggested.
The FDA's warning is intended to protect the well-being of consumers, urging caution and vigilance when choosing products for blood glucose management.
